Keratoconjunctivitis sicca Dry Eye-Pipeline Review, H1 2016

Keratoconjunctivitis sicca Dry Eye-Pipeline Review, H1 2016


  • Products Id :- GMDHC7708IDB
  • |
  • Pages: 193
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H1 2016', provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects

The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Keratoconjunctivitis sicca (Dry Eye) Overview 9

Therapeutics Development 10

Pipeline Products for Keratoconjunctivitis sicca (Dry Eye)-Overview 10

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics under Development by Companies 11

Keratoconjunctivitis sicca (Dry Eye)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Keratoconjunctivitis sicca (Dry Eye)-Products under Development by Companies 19

Keratoconjunctivitis sicca (Dry Eye)-Companies Involved in Therapeutics Development 23

AB2 Bio Ltd. 23

Akari Therapeutics, Plc 24

Allergan Plc 25

Circadian Technologies Limited 26

Delenex Therapeutics AG 27

Digna Biotech, S.L. 28

Dompe Farmaceutici S.p.A. 29

HanAll Biopharma Co., Ltd. 30

Herantis Pharma Plc 31

Huons Co., Ltd. 32

InSite Vision Incorporated 33

Kala Pharmaceuticals, Inc. 34

Kissei Pharmaceutical Co., Ltd. 35

Kukje Pharmaceutical Industry Co., Ltd. 36

Laboratorios Sophia S.A. de C.V. 37

Lee's Pharmaceutical Holdings Limited 38

Lipicard Technologies Limited 39

Merck & Co., Inc. 40

Mimetogen Pharmaceuticals Inc. 41

Mitotech S.A. 42

Nanomerics Ltd 43

Neuroptis Biotech 44

Novaliq GmbH 45

Ocular Therapeutix, Inc. 46

Oculis ehf 47

OncoNOx ApS 48

Otsuka Holdings Co., Ltd. 49

Parion Sciences, Inc. 50

PharmaReaserch Products Co., Ltd. 51

RegeneRx Biopharmaceuticals, Inc. 52

Rigel Pharmaceuticals, Inc. 53

Samjin Pharmaceutical Co., Ltd. 54

Santen Pharmaceutical Co., Ltd. 55

Seikagaku Corporation 56

Shire Plc 57

Sucampo Pharmaceuticals, Inc. 58

TearSolutions, LLC. 59

Xigen SA 60

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Assessment 61

Assessment by Monotherapy Products 61

Assessment by Target 62

Assessment by Mechanism of Action 65

Assessment by Route of Administration 68

Assessment by Molecule Type 70

Drug Profiles 72

AGN-223575-Drug Profile 72

AGN-232411-Drug Profile 73

AVX-012-Drug Profile 74

Ax-8-Drug Profile 75

BRM-421-Drug Profile 76

cinhyaluronate sodium-Drug Profile 77

Cis-Urocanic Acid-Drug Profile 78

Cryosim-3-Drug Profile 81

cyclosporine-Drug Profile 82

cyclosporine-Drug Profile 83

cyclosporine-Drug Profile 86

cyclosporine-Drug Profile 87

cyclosporine-Drug Profile 88

cyclosporine-Drug Profile 89

cyclosporine-Drug Profile 90

dexamethasone acetate SR-Drug Profile 91

diclofenac sodium-Drug Profile 92

diquafosol tetrasodium-Drug Profile 93

disitertide-Drug Profile 95

DLX-105-Drug Profile 98

DMT-220-Drug Profile 100

HL-036-Drug Profile 101

HU-007-Drug Profile 102

ISV-101-Drug Profile 103

KeraKlear-Drug Profile 104

KJ-14003-Drug Profile 105

KL-7016-Drug Profile 106

KPI-190-Drug Profile 107

Lacripep-Drug Profile 108

lifitegrast-Drug Profile 109

LME-636-Drug Profile 112

loteprednol etabonate-Drug Profile 113

NOP-3-Drug Profile 115

NOP-5-Drug Profile 116

Nov-03-Drug Profile 117

OC-301-Drug Profile 118

OPX-1-Drug Profile 119

OX-1001-Drug Profile 120

ozagrel-Drug Profile 121

P-321-Drug Profile 122

plastoquinone decyl triphenylphosphonium bromide-Drug Profile 123

PPL-003-Drug Profile 125

PRD-005-Drug Profile 127

PRO-148-Drug Profile 128

Qi-204-Drug Profile 129

R-348-Drug Profile 130

rebamipide-Drug Profile 131

Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology-Drug Profile 133

RGN-259-Drug Profile 135

RP-101-Drug Profile 137

RU-101-Drug Profile 138

SA-001-Drug Profile 139

tadekinig alfa-Drug Profile 140

tavilermide hydrochloride-Drug Profile 141

VGX-100-Drug Profile 142

XG-104-Drug Profile 145

ZK-003-Drug Profile 146

zucapsaicin-Drug Profile 147

Keratoconjunctivitis sicca (Dry Eye)-Recent Pipeline Updates 149

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects 177

Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products 182

Keratoconjunctivitis sicca (Dry Eye)-Product Development Milestones 183

Featured News & Press Releases 183

Appendix 188

Methodology 188

Coverage 188

Secondary Research 188

Primary Research 188

Expert Panel Validation 188

Contact Us 188

Disclaimer 189

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Comparative Analysis by Late Stage Development, H1 2016 19

Comparative Analysis by Clinical Stage Development, H1 2016 20

Comparative Analysis by Early Stage Products, H1 2016 21

Assessment by Monotherapy Products, H1 2016 65

Number of Products by Top 10 Targets, H1 2016 66

Number of Products by Stage and Top 10 Targets, H1 2016 66

Number of Products by Top 10 Mechanism of Actions, H1 2016 69

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 69

Number of Products by Top 10 Routes of Administration, H1 2016 72

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 72

Number of Products by Top 10 Molecule Types, H1 2016 74

Number of Products by Stage and Top 10 Molecule Types, H1 2016 74

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2016 14

Number of Products under Development by Companies, H1 2016 16

Number of Products under Development by Companies, H1 2016 (Contd..1) 17

Number of Products under Development by Companies, H1 2016 (Contd..2) 18

Comparative Analysis by Late Stage Development, H1 2016 19

Comparative Analysis by Clinical Stage Development, H1 2016 20

Comparative Analysis by Early Stage Development, H1 2016 21

Comparative Analysis by Unknown Stage Development, H1 2016 22

Products under Development by Companies, H1 2016 23

Products under Development by Companies, H1 2016 (Contd..1) 24

Products under Development by Companies, H1 2016 (Contd..2) 25

Products under Development by Companies, H1 2016 (Contd..3) 26

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by AB2 Bio Ltd., H1 2016 27

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Akari Therapeutics, Plc, H1 2016 28

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Allergan Plc, H1 2016 29

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Circadian Technologies Limited, H1 2016 30

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Delenex Therapeutics AG, H1 2016 31

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Digna Biotech, S.L., H1 2016 32

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Dompe Farmaceutici S.p.A., H1 2016 33

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by HanAll Biopharma Co., Ltd., H1 2016 34

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Herantis Pharma Plc, H1 2016 35

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Huons Co., Ltd., H1 2016 36

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by InSite Vision Incorporated, H1 2016 37

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kala Pharmaceuticals, Inc., H1 2016 38

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 39

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016 40

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Laboratorios Sophia S.A. de C.V., H1 2016 41

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 42

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Lipicard Technologies Limited, H1 2016 43

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Merck & Co., Inc., H1 2016 44

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Mimetogen Pharmaceuticals Inc., H1 2016 45

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Mitotech S.A., H1 2016 46

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Nanomerics Ltd, H1 2016 47

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Neuroptis Biotech, H1 2016 48

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Novaliq GmbH, H1 2016 49

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Ocular Therapeutix, Inc., H1 2016 50

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Oculis ehf, H1 2016 51

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by OncoNOx ApS, H1 2016 52

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Otsuka Holdings Co., Ltd., H1 2016 53

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Parion Sciences, Inc., H1 2016 54

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by PharmaReaserch Products Co., Ltd., H1 2016 55

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 56

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 57

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Samjin Pharmaceutical Co., Ltd., H1 2016 58

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 59

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Seikagaku Corporation, H1 2016 60

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Shire Plc, H1 2016 61

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 62

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by TearSolutions, LLC., H1 2016 63

Keratoconjunctivitis sicca (Dry Eye)-Pipeline by Xigen SA, H1 2016 64

Assessment by Monotherapy Products, H1 2016 65

Number of Products by Stage and Target, H1 2016 67

Number of Products by Stage and Mechanism of Action, H1 2016 70

Number of Products by Stage and Route of Administration, H1 2016 73

Number of Products by Stage and Molecule Type, H1 2016 75

Keratoconjunctivitis sicca (Dry Eye) Therapeutics-Recent Pipeline Updates, H1 2016 153

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects, H1 2016 181

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects (Contd..1), H1 2016 182

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects (Contd..2), H1 2016 183

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects (Contd..3), H1 2016 184

Keratoconjunctivitis sicca (Dry Eye)-Dormant Projects (Contd..4), H1 2016 185

Keratoconjunctivitis sicca (Dry Eye)-Discontinued Products, H1 2016 186

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AB2 Bio Ltd. Akari Therapeutics, Plc Allergan Plc Circadian Technologies Limited Delenex Therapeutics AG Digna Biotech, S.L. Dompe Farmaceutici S.p.A. HanAll Biopharma Co., Ltd. Herantis Pharma Plc Huons Co., Ltd. InSite Vision Incorporated Kala Pharmaceuticals, Inc. Kissei Pharmaceutical Co., Ltd. Kukje Pharmaceutical Industry Co., Ltd. Laboratorios Sophia S.A. de C.V. Lee's Pharmaceutical Holdings Limited Lipicard Technologies Limited Merck & Co., Inc. Mimetogen Pharmaceuticals Inc. Mitotech S.A. Nanomerics Ltd Neuroptis Biotech Novaliq GmbH Ocular Therapeutix, Inc. Oculis ehf OncoNOx ApS Otsuka Holdings Co., Ltd. Parion Sciences, Inc. PharmaReaserch Products Co., Ltd. RegeneRx Biopharmaceuticals, Inc. Rigel Pharmaceuticals, Inc. Samjin Pharmaceutical Co., Ltd. Santen Pharmaceutical Co., Ltd. Seikagaku Corporation Shire Plc Sucampo Pharmaceuticals, Inc. TearSolutions, LLC. Xigen SA

Keratoconjunctivitis sicca (Dry Eye) Therapeutic Products under Development, Key Players in Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Keratoconjunctivitis sicca (Dry Eye) Pipeline Overview, Keratoconjunctivitis sicca (Dry Eye) Pipeline, Keratoconjunctivitis sicca (Dry Eye) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com